about
WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lungHuman LPLUNC1 is a secreted product of goblet cells and minor glands of the respiratory and upper aerodigestive tractsReactive oxygen species and hyaluronidase 2 regulate airway epithelial hyaluronan fragmentationGenes and chronic obstructive pulmonary diseaseDifferential epithelial expression of the putative innate immune molecule SPLUNC1 in cystic fibrosisActive trafficking of alpha 1 antitrypsin across the lung endotheliumClimate Change and Respiratory Infections.Alpha-1 antitrypsin supplementation improves alveolar macrophages efferocytosis and phagocytosis following cigarette smoke exposure.Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency.α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.Microbial "social networks".Pulmonary artery rupture induced by a pulmonary artery catheter: a case report and review of the literature.The rationale for pharmacologic therapy in stable chronic obstructive pulmonary disease.Concurrent PCP and TB pneumonia in HIV infected patients.The Association between ESR and CRP and Systemic Hypertension in SarcoidosisProtein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner.Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation.Improving adherence to alpha-1 antitrypsin deficiency screening guidelines using the pulmonary function laboratory.Body habitus in patients with and without bronchiectasis and non-tuberculous mycobacteria.Airway blood flow reactivity in smokers.Roflumilast partially reverses smoke-induced mucociliary dysfunction.Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation.Acute lung injury outside of the ICU: incidence in respiratory isolation on a general ward.A Patient-Based Analysis of the Geographic Distribution of Mycobacterium avium complex, Mycobacterium abscessus, and Mycobacterium kansasii Infections in the United States.Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma.Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy.Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.SPLUNC1 (PLUNC) is expressed in glandular tissues of the respiratory tract and in lung tumours with a glandular phenotype.Weaning parameters: read the methodology before proceeding.Differences in vaping topography in relation to adherence to exclusive electronic cigarette use in veterans.Detection of alpha-1 antitrypsin deficiency in the US.Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003Feasibility of shortening respiratory isolation with a single sputum nucleic acid amplification testInfluenza vaccination in subjects with alpha1-antitrypsin deficiencyInterferon-induced sarcoidosisClinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years
P50
Q21284411-8DE26878-3C28-4677-8CB7-53AD76DD9F61Q24303669-928FA1BE-5DAE-4457-8E41-EFFCF82FAE02Q24322530-CE4C7AF2-3588-4876-837F-4A2B9BCAC9E7Q24630805-1D085060-A2C3-4EB8-BE57-8AEE6C2DE23BQ24649836-74A18166-BC8F-4095-8E33-5CBE3D83E3DBQ27343637-8CD35A24-8353-45A3-9D89-C959632AABBFQ31107998-E3E6726D-4586-4740-B03B-B30A4D321A0EQ33610265-BB4D349C-2E85-4646-89A6-A4E7168A3DB3Q33710034-5BD3801B-9485-4502-88E8-7BB23A9F9E3CQ34428735-A4A7777F-D875-45B9-AFBA-C93239B2B1FAQ34948784-273FD683-EF04-4EDE-89C3-26B48DFC417CQ35044708-DA0C65DE-34E5-4D6F-998A-558C98762CE7Q35844002-91915E46-9604-423D-849D-1D4416D5474BQ35883417-B1671983-10CB-45FD-86E4-887FE8A2404DQ36098829-07CF3CF3-69CA-4232-8FD4-4145B4AEED52Q36939689-44306F11-4069-4660-BA7E-EA9E9805B44BQ37084299-63578DB9-C885-486A-AA41-4C2B4002DD50Q37131583-CEC15167-C6E1-4D40-B172-D6D7D5E60718Q37471700-30BD5B11-20F3-4341-A5B2-697B7DE096B6Q37702957-4FDB289A-8842-41EF-8929-DA6116D7098FQ41276677-76CFA285-EB17-4554-B43A-68561FA73074Q41993428-6950316E-34C6-4930-825B-912644538A22Q42171390-D1734909-35AA-4A1D-9911-7F1E707C9567Q43194351-8E5A5408-0A5A-49FC-8B80-21253C500C8DQ43680196-C3EF45CC-D079-4562-A4CA-1C370E23D7F3Q44364967-040D735D-4A54-48BE-9649-588A01A85521Q45056684-0BAAC719-3D77-41ED-9FEE-165BF3352750Q46774150-8D7F6551-66A5-4E35-A81F-9F62F695404FQ46845595-7B4C2D4F-B97A-4E3D-B9E4-4F728E132322Q47703811-AD82E229-FC13-4F4E-9B1C-C8196DD72E82Q47740528-A49CB563-20E9-4214-AB4A-BA29AC2703FEQ47855911-33EFF231-8E76-48F9-A867-84B21F8786EFQ51694630-54810615-7C63-4C67-9D0B-19F46C182FF8Q52318421-B3F828A5-10F7-4F23-8819-6820E967D01EQ54774949-F037F29B-E020-414E-8F05-CE95A47F5E6FQ81215627-BAC1E1B3-DE23-4705-AA71-59E1846F2B0AQ81243498-6336AD5F-9AA3-47F8-AE4B-F865A83826E0Q81380812-431F7A6A-84F5-4AE1-984B-5EDF57F8C957Q82442869-B45BC766-F24E-4645-B192-EB09C8BE6C14Q82650244-1398EC1F-B34E-469E-B562-C4EFF6EE0FB3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael A. Campos
@ast
Michael A. Campos
@en
Michael A. Campos
@es
Michael A. Campos
@nl
Michael A. Campos
@sl
type
label
Michael A. Campos
@ast
Michael A. Campos
@en
Michael A. Campos
@es
Michael A. Campos
@nl
Michael A. Campos
@sl
prefLabel
Michael A. Campos
@ast
Michael A. Campos
@en
Michael A. Campos
@es
Michael A. Campos
@nl
Michael A. Campos
@sl
P106
P1153
7202803614
P21
P31
P496
0000-0001-5485-9062